Literature DB >> 33742373

Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions.

Hans Theodor Eich1,2, Kambiz Rahbar3,2, Sergiu Scobioala4,5, Christopher Kittel1,2, Heidi Wolters1,2, Sebastian Huss6,2, Khaled Elsayad1,2, Robert Seifert3,2, Lars Stegger3,2, Matthias Weckesser3,2, Uwe Haverkamp1,2.   

Abstract

OBJECTIVE: The objective of this study was to assess the accuracy of 68Ga-PSMA-11 PET/MRI, 18F-PSMA-1007 PET/CT, 68Ga-PSMA-11 PET/CT, and multiparametric (mp)MRI for the delineating of dominant intraprostatic lesions (IPL).
MATERIALS AND METHODS: 35 patients with organ-confined prostate cancer who were assigned to definitive radiotherapy (RT) were divided into three groups based on imaging techniques: 68Ga-PSMA-PET/MRI (n = 9), 18F-PSMA-PET/CT (n = 16) and 68Ga-PSMA-PET/CT (n = 10). All patients without PSMA-PET/MRI received an additional mpMRI. PSMA-PET-based automatic isocontours and manual contours of the dominant IPLs were generated for each modality. The biopsy results were then used to validate whether any of the prostate biopsies were positive in the marked lesion using Dice similarity coefficient (DSC), Youden index (YI), sensitivity and specificity. Factors that can predict the accuracy of IPLs contouring were analysed.
RESULTS: Diagnostic performance was significantly superior both for manual and automatic IPLs contouring using 68Ga-PSMA-PET/MRI (DSC/YI SUV70%-0.62/0.51), 18F-PSMA-PET/CT (DSC/YI SUV70%-0.67/0.53) or 68Ga-PSMA-PET/CT (DSC/YI SUV70%-0.63/0.51) compared to mpMRI (DSC/YI-0.47/0.41; p < 0.001). The accuracy for delineating IPLs was not improved by combination of PET/CT and mpMRI images compared to PET/CT alone. Significantly superior diagnostic accuracy was found for large prostate lesions (at least 15% from the prostate volume) and higher Gleason score (at least 7b) comparing to smaller lesions with lower GS.
CONCLUSION: IPL localization was significantly improved when using PSMA-imaging procedures compared to mpMRI. No significant difference for delineating IPLs was found between hybrid method PSMA-PET/MRI and PSMA-PET/CT. PSMA-based imaging technique should be considered for the diagnostics of IPLs and focal treatment modality.

Entities:  

Keywords:  Biopsy-derived landmarks; Hybrid imaging; Multiparametric MRI; PSMA-PET; Prostate cancer

Year:  2021        PMID: 33742373     DOI: 10.1007/s12149-021-01606-7

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  44 in total

1.  Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?

Authors:  Laura Van den Bergh; Michel Koole; Sofie Isebaert; Steven Joniau; Christophe M Deroose; Raymond Oyen; Evelyne Lerut; Tom Budiharto; Felix Mottaghy; Guy Bormans; Hendrik Van Poppel; Karin Haustermans
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-26       Impact factor: 7.038

Review 2.  68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer.

Authors:  Simona Malaspina; Ugo De Giorgi; Jukka Kemppainen; Angelo Del Sole; Giovanni Paganelli
Journal:  Radiol Med       Date:  2018-08-16       Impact factor: 3.469

3.  Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.

Authors:  Claudia Kesch; Maria Vinsensia; Jan P Radtke; Heinz P Schlemmer; Martina Heller; Elena Ellert; Tim Holland-Letz; Stefan Duensing; Nils Grabe; Ali Afshar-Oromieh; Kathrin Wieczorek; Martin Schäfer; Oliver C Neels; Jens Cardinale; Clemens Kratochwil; Markus Hohenfellner; Klaus Kopka; Uwe Haberkorn; Boris A Hadaschik; Frederik L Giesel
Journal:  J Nucl Med       Date:  2017-05-04       Impact factor: 10.057

4.  Comparison of [(11)C]choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions.

Authors:  Joe H Chang; Daryl Lim Joon; Ian D Davis; Sze Ting Lee; Chee-Yan Hiew; Stephen Esler; Sylvia J Gong; Morikatsu Wada; David Clouston; Richard O'Sullivan; Yin P Goh; Damien Bolton; Andrew M Scott; Vincent Khoo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-08       Impact factor: 7.038

Review 5.  New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

Authors:  Laura Evangelista; Alberto Briganti; Stefano Fanti; Stephen Joniau; Sven Reske; Riccardo Schiavina; Christian Stief; George N Thalmann; Maria Picchio
Journal:  Eur Urol       Date:  2016-02-02       Impact factor: 20.096

6.  Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy.

Authors:  Takako Yamaguchi; Jin Lee; Hiroji Uemura; Takeshi Sasaki; Nobukazu Takahashi; Takashi Oka; Kazuya Shizukuishi; Hisashi Endou; Yoshinobu Kubota; Tomio Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-15       Impact factor: 9.236

7.  [68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer.

Authors:  Alisa S Bettermann; Constantinos Zamboglou; Selina Kiefer; Cordula A Jilg; Simon Spohn; Jasmin Kranz-Rudolph; Thomas F Fassbender; Peter Bronsert; Nils H Nicolay; Christian Gratzke; Michael Bock; Juri Ruf; Matthias Benndorf; Anca L Grosu
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

8.  Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference.

Authors:  Constantinos Zamboglou; Thomas F Fassbender; Lina Steffan; Florian Schiller; Tobias Fechter; Montserrat Carles; Selina Kiefer; Hans C Rischke; Kathrin Reichel; Nina-Sophie Schmidt-Hegemann; Harun Ilhan; Alin F Chirindel; Guillaume Nicolas; Christoph Henkenberens; Thorsten Derlin; Peter Bronsert; Panayiotis Mavroidis; Ronald C Chen; Philipp T Meyer; Juri Ruf; Anca L Grosu
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

9.  Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

Authors:  Matthias Eiber; Gregor Weirich; Konstantin Holzapfel; Michael Souvatzoglou; Bernhard Haller; Isabel Rauscher; Ambros J Beer; Hans-Jürgen Wester; Juergen Gschwend; Markus Schwaiger; Tobias Maurer
Journal:  Eur Urol       Date:  2016-01-18       Impact factor: 20.096

10.  Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.

Authors:  Claudia Testa; Riccardo Schiavina; Raffaele Lodi; Eugenio Salizzoni; Barbara Corti; Mohsen Farsad; John Kurhanewicz; Fabio Manferrari; Eugenio Brunocilla; Caterina Tonon; Nino Monetti; Paolo Castellucci; Stefano Fanti; Manuela Coe; Walter F Grigioni; Giuseppe Martorana; Romeo Canini; Bruno Barbiroli
Journal:  Radiology       Date:  2007-07-24       Impact factor: 11.105

View more
  2 in total

1.  Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour.

Authors:  Mathieu Gaudreault; David Chang; Nicholas Hardcastle; Price Jackson; Tomas Kron; Michael S Hofman; Shankar Siva
Journal:  Clin Transl Radiat Oncol       Date:  2022-05-17

2.  Time point-independent tumor positivity of 68Ga-PSMA-PET/CT pre- and post-biopsy in high-risk prostate cancer.

Authors:  Sijuan Zou; Shuang Song; Jianyuan Zhou; Bo Yu; Dong Kuang; Zhihua Wang; Xiaohua Zhu
Journal:  Ann Nucl Med       Date:  2022-04-01       Impact factor: 2.258

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.